• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

FX-345

Phase 1b study of FX-345, new hearing loss drug candidate from Frequency Therapeutics, planned for second half of 2022

January 15, 2022

FX-345 program will “enable the company to clinically evaluate increased cochlear coverage across range of doses in multiple patient populations,” according to a recent presentation uploaded to the Frequency Therapeutics website.

Background:

FX-345 is Frequency Therapeutics’ second clinical program for sensorineural hearing loss, focused on the regrowth of sensory cells. The drug is being developed in addition to FX-322 (important distinction). Based on what we have been told so far, the big idea behind FX-345 — and its potential to restore hearing in SNHL patients — seems to be related to increased cochlear coverage. This particular aspect of the new drug candidate is repeated throughout the three-page FX-345 section of the presentation:

  • “Broad Exposure Through the Cochlea”
  • “Enables coverage of large portion of cochlea”
  • “Through Large Portion of Cochlea”

That’s the idea, anyway. But, as the presentation also points out:

  • “Clinical data will drive commercial positioning”

A good reminder and also a good reason to look forward to the second half of the year, when the phase 1 trial is slated to begin…

Sneak preview of the full presentation (pages 28 to 30):

FX-345 presentation preview

Below is a link to the full “Corporate Presentation – January 22” from Frequency Therapeutics. It is a 57-page PDF document but go to page 28 if you only want to read the FX-345 section (three pages, total):

https://investors.frequencytx.com/static-files/82a80eb8-8cd7-443b-a9c7-7c19d0d1b99d

What happens next?

For updates on the development status of FX-345 — and other promising new treatments currently in development for sensorineural hearing loss — subscribe to the newsletter (email updates). It’s free, your information is kept private and not shared or sold to third parties… no spam or sponsored content… Instead, it’s a way to get “nothing but new treatment updates”, and only when something important happens.

Frequency Therapeutics Highlights Clinical Advancement of FX-322 and Unveils FX-345, a New Potential Restorative Treatment for Hearing Loss

November 9, 2021

Frequency Therapeutics Highlights Clinical Advancement of FX-322 and Unveils FX-345, a New Potential Restorative Treatment for Hearing Loss
November 9, 2021
https://investors.frequencytx.com/news-releases/news-release-details/frequency-therapeutics-holds-virtual-rd-event-highlighting

Comments from the CEO:
“We will also unveil two new research programs that demonstrate the potential of our progenitor cell activation (PCA) approach. First, we will introduce FX-345, a new hearing restoration candidate designed for greater distribution through the cochlea, potentially enabling the treatment of expanded SNHL patient populations.”

Highlights from the press release, copy+pasted:

“FX-345
Introduction of new SNHL investigational therapeutic program, including a more potent GSK3 inhibitor designed to achieve broader exposure of the cochlea.

Powered by Urgent Research

Copyright © 2025 Urgent Research